Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease
Recruiting
Phase 2
Interventional Study
Dry Eye Disease
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 128 (estimated)
- Sponsor
- Beijing Tongren Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Objective: To evaluate the effect of transcutaneous auricular vagus nerve stimulation (taVNS) for the patients with dry eye disease with meibomian gland dysfunction.
Methods: We enrolled 256 patients at Beijing Tongren Hospital. Patients completed questionnaires at baseline, 1 month, 3 months, and 6 months.OSDI score, TBUT, Schirmer I, tCFS, MGD score, and psychological status to evaluate the the…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age \>=18 and Age \<=75.
2. Clinical diagnosis of dry eye disease.
Exclusion Criteria:
1. History of depression, tumors, thyroid disease, diabetes, cardiac diseases.
2. History of phthalmology surgery.
3. Pregnant or lactating women.
Contacts